HEOR

News

CSL Behring's Andembry can be used to prevent recurrent attacks of HAE by the NHS, following finalised guidance from reimbursement authority NICE.

News

Digital health tech for opioid use disorder can be as effective as regular care, but it doesn't expand access and may increase the cost of care.

News

AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer.

News

Novo Nordisk and Eli Lilly's GLP-1s offer big health benefits and are cost-effective at current US prices, but affordability remains an issue.

News

Six digital cardiac rehabilitation programmes can be used by the NHS in England, but more data is needed on seven others, says NICE.

News

NICE backs NHS use of an AstraZeneca drug for one rare disease, but says it can't recommend a BioMarin therapy for another.